Glucagon’s Ketogenic Effect: A Technical Pros and Cons Analysis
Abstract: Glucagon’s ketogenic effect, driven by hepatic glycogenolysis and fatty acid oxidation, presents a dual-edged technical profile. Pros include rapid ketone body elevation for therapeutic use in metabolic disorders, with clinical data showing a 3-fold increase in β-hydroxybutyrate within 30 minutes. Cons involve hyperglycemic rebound and limited half-life ( 6 minutes), complicating formulation stability. Market trends indicate a 12.4% CAGR in glucagon-based peptide products, with brands like Eli Lilly and Zealand Pharma leading in purity (>98%) and cold-chain logistics. Technical comparisons highlight superior efficacy in acute settings versus GLP-1 analogs, yet require stringent storage (-20°C) and multi-dose vial certifications (FDA, EMA). For product selection, prioritize lyophilized formulations with ≥95% peptide content and validated stability data. Industry challenges include high manufacturing costs and regulatory hurdles, but expanding applications in cachexia and diabetic ketoacidosis drive growth.